

RP01363

Leader in Biomolecular Solutions for Life Science



Recombinant Human IGFBP-3 Protein

Catalog No.: RP01363

Recombinant

Sequence Information

Species	Gene ID	Swiss Prot
HEK293 cells	3486	P17936-1

Tags

C-His

Synonyms

IGFBP3;BP-53;IBP3

Product Information

Source	Purification
	> 95% by SDS-PAGE.

Endotoxin

<1EU/μg

Formulation

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact



www.abclonal.com

Background

The Insulin-like Growth Factor (IGF) signaling system plays a central role in cellular growth, differentiation, and proliferation. IGFBP3 is the most abundant IGF binding protein in human serum and is a growth inhibitory, apoptosis-inducing molecule, capable of acting via IGF-dependent and IGF-independent mechanisms. It appears to function both by cell cycle blockade and the induction of apoptosis. IGFBP3 can be transported to the nucleus by an importin beta mediated mechanism, where it has been shown to interact with the retinoid X receptor alpha and possibly other nuclear elements. IGFBP3 antiproliferative signaling appears to require an active transforming growth factor-beta (TGF-beta) signaling pathway, and IGFBP3 stimulates phosphorylation of the TGF-beta signaling intermediates Smad2 and Smad3. IGFBP3 has IGF-independent roles in inhibiting cell proliferation in cancer cell lines. Nuclear transcription factor, retinoid X receptor (RXR)-alpha, and IGFBP3 functionally interact to reduce prostate tumor growth and prostate-specific antigen in vivo. Several clinical studies have proposed that individuals with IGFBP3 levels in the upper range of normal may have a decreased risk for certain common cancers. This includes evidence of a protective effect against breast cancer, prostate cancer, colorectal cancer, and lung cancer. Moreover, IGFBP3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF.

Basic Information

Description

Recombinant Human IGFBP-3 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly28-Lys291) of human IGFBP3/BP-53 (Accession #NP_000589.2) fused with a 6×His tag at the C-terminus.

Bio-Activity


Measured by its binding ability in a functional ELISA. Immobilized Human IGFBP3 Protein at 1 μg/mL (100 μL/well) can bind IGF1 with a linear range of 0.158-23.05ng/mL.

Storage


Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week. Avoid repeated freeze/thaw cycles.

* For your safety and health, please wear a lab coat and disposable gloves when handling.

Validation Data



Recombinant Human IGFBP-3 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 40-50kDa.



Immobilized Human IGFBP3 Protein at 1 µg/mL (100 µL/well) can bind IGF1 with a linear range of 0.158-23.05ng/mL.